Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: A mixed treatment comparison meta-analysis of 7258 patients

Hematological Oncology

Volumn 33, Issue 4, 2015, Pages 212-219

  Sekine, Leo ^a,c   Morais, Vinícius Daudt ^a   Lima, Karine Margarites ^a,c   Onsten, Tor Gunnar Hugo ^a   Ziegelmann, Patrícia Klarmann ^a,b   Ribeiro, Rodrigo Antonini ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b National Institute of Science and Technology for Health Technology Assessment (IATS) CNPq   (Brazil)

^c HOSPITAL MOINHOS DE VENTO   (Brazil)

Author keywords

Acute myeloid leukaemia; Anthracyclines; Daunorubicin; Idarubicin; Induction chemotherapy; Remission induction

Indexed keywords

DAUNORUBICIN; IDARUBICIN; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COMPARATIVE STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; DISEASE FREE SURVIVAL; FEMALE; LEUKEMIA, MYELOID, ACUTE; MALE; MORTALITY; PATHOLOGY; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; REMISSION INDUCTION;

EID: 84954559849     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2173     Document Type: Article

References (37)

1. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther 2011; 33(3): 254-279.
2. Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007; 7(2): 56-60.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.
4. Minotti G, Sarvazyan N. The anthracyclines: when good things go bad. Cardiovasc Toxicol 2007; 7(2): 53-55.
5. Beutler E. The treatment of acute leukemia: past, present, and future. Leukemia 2001; 15(4): 658-661.
6. Buchner T, Schlenk RF, Schaich M, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML intergroup. J Clin Oncol 2012; 30(29): 3604-3610.
7. Hoffman R. Hematology: Basic Principles and Practice (5th edn). Churchill Livingstone/Elsevier: Philadelphia, PA, 2009.
8. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013; 161(2): 192-203.
9. Wang J, Yang YG, Zhou M, et al. Meta-analysis of randomised clinical trials comparing idarubicin+cytarabine with daunorubicin+cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PLoS One 2013; 8(4): e60699.
10. Wheatley K. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998; 103(1): 100-109.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151(4): 264-269, W64.
12. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 2005; 330(7501): 1179-1184.
13. Wilczynski NL, Haynes RB. Response to Corrao et al.: Improving efficacy of PubMed clinical queries for retrieving scientifically strong studies on treatment. J Am Med Inform Assoc 2007; 14(2): 247-248.
14. Wilczynski NL, McKibbon KA, Haynes RB. Response to Glanville et al.: How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc 2007; 95(2): 117-118; author reply 9-20.
15. Higgins JPT, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell: Chichester, England; Hoboken, NJ, 2008.
16. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23(20): 3105-3124.
17. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29(7-8): 932-944.
18. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77(8): 1666-1674.
19. Chevallier P, Fornecker L, Lioure B, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24(7): 1380-1385.
20. Eridani S, Singh AK, Slater NGP, et al. A phase II study of idarubicin versus daunorubicin in the treatment of acute non-lymphocytic leukaemia. Cancer J 1989; 2(9): 296-298.
21. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361(13): 1249-1259.
22. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109(12): 5129-5135.
23. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118(14): 3832-3841.
24. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361(13): 1235-1248.
25. Mandelli F, Petti MC, Ardia A, et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer (Oxford, England: 1990) 1991; 27(6): 750-755.
26. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27(32): 5397-5403.
27. Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol 1996; 33(4 Suppl 3): 12-17.
28. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011; 117(8): 2358-2365.
29. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70years: results of the ALFA-9801 study. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28(5): 808-814.
30. Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia, Leukemia Research Fund, UK. 1996; 10(3): 389-395.
31. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103(2): 479-485.
32. Rubio E, González J, Ovilla R, Delgado J, Bernal J, Grupo multicéntrico mexicano I. De novo acute myeloblastic leukemia: response to induction chemotherapy: a comparative study between idarubicin vs. daunorubicin. Sangre 1993; 38(1): 80.
33. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol Off J Am Soc Clin Oncol 1992; 10(7): 1103-1111.
34. Wiernik PH, Banks PL, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79(2): 313-319.
35. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012; 120(16): 3187-3205.
36. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol 2012; 159(3): 259-276.
37. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60(2): 454-462.